INVEGA TRINZA® Metabolic Data Observed
Metabolic Change Data: Long-term Maintenance Trial1
![metabolic-data-weight-change](https://www.invegatrinzahcp.com/sites/www.invegatrinzahcp-v2.com/files/metabolic-data-weight-change-1.png)
*During the open-label phase, patients received several doses of INVEGA SUSTENNA® (paliperidone palmitate) followed by a single dose of INVEGA TRINZA®.
WEIGHT GAIN: Weight gain has been reported with atypical antipsychotic use. Clinical monitoring of weight is recommended.1
Fasting Glucose1
![metabolic-data-long-term](https://www.invegatrinzahcp.com/sites/www.invegatrinzahcp-v2.com/files/2-2-metabolic-data-long-term.png)
*During the open-label phase, patients received several doses of INVEGA SUSTENNA® followed by a single dose of INVEGA TRINZA®.
Hyperglycemia and Diabetes Mellitus1
- Monitor for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness
- Monitor glucose regularly in patients with diabetes or at risk for diabetes
Fasting Lipids1
![fasting-lipids](https://www.invegatrinzahcp.com/sites/www.invegatrinzahcp-v2.com/files/2-2-fasting-lipids.png)
DYSLIPIDEMIA: Undesirable alterations in lipids have been observed in patients treated with antipsychotics.1
Please see additional Important Safety Information below.
*Values for the open-label phase and the double-blind phase are relative to their respective baselines.
†During the open-label phase, patients received several doses of INVEGA SUSTENNA® followed by a single dose of INVEGA TRINZA®.
Reference: 1. INVEGA TRINZA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; August 2021.